Addressing Weight-Loss Plateaus: GDF-8 and GDF-15 as Emerging Targets for Fat Reduction and Metabolic Function

Background

While GLP-1–based therapies have driven a surge of interest due to their robust weight-loss efficacy, treatment-associated muscle loss is emerging as a significant clinical concern. Evidence suggests that 25–40% of weight reduction induced by GLP-1 receptor agonists may be attributable to lean mass loss, which can compromise metabolic health and contribute to rapid weight regain following treatment discontinuation. Against this backdrop, GDF-8 and GDF-15 have emerged as promising next-generation targets. Their distinct biological mechanisms position them as potential key strategies for improving body composition and advancing more metabolically favorable weight-loss interventions.

GDF-8: A Key Target for Addressing Weight-Loss–Associated Muscle Loss

GDF-8, also known as myostatin (MSTN), is a central regulator of skeletal muscle growth and a member of the transforming growth factor-β (TGF-β) superfamily. Its primary biological function is to inhibit myoblast proliferation and differentiation, thereby maintaining dynamic control of muscle mass. Under physiological conditions, GDF-8 exerts its effects through binding to activin type II receptors (Activin RIIA and Activin RIIB). In weight-loss settings such as caloric restriction or GLP-1–based therapy, activation of the GDF-8 signaling pathway is often upregulated as part of an energy-conservation response. This enhanced signaling accelerates skeletal muscle catabolism, contributing to the well-recognized challenge of lean mass loss during fat reduction.

https://doi.org/10.1007/s11033-025-11390-6

Loss of muscle homeostasis via overactive myostatin signaling in sarcopenia

To address this challenge, a key strategy is inhibition of the GDF-8 signaling pathway to promote a more favorable balance between muscle preservation and fat reduction. A cross-species study published in Nature (May 2025) demonstrated that in obese mice and nonhuman primates, combining a GLP-1 receptor agonist (e.g., semaglutide) with blockade of GDF-8 and Activin A signaling significantly improved the quality of weight loss. This approach reduced lean mass loss while enhancing fat mass reduction, resulting in weight loss outcomes more closely aligned with metabolic health objectives.

https://doi.org/10.1038/s41467-025-59485-9

Myostatin and activin A blockade induce additive fat mass loss with semaglutide in DIO mice

Several GDF-8–targeted therapies are currently in clinical development worldwide, encompassing modalities such as fully human monoclonal antibodies and fusion proteins. Indications extend beyond obesity and muscle wasting to neuromuscular disorders including spinal muscular atrophy and Duchenne muscular dystrophy. Among the leading programs, Scholar Rock’s apitegromab is the most advanced candidate, while other agents such as Emugrobart and Talditercept alfa have progressed into late-stage clinical trials. In parallel, additional candidates remain in preclinical development, with some programs exploring dual blockade of GDF-8 and Activin RIIA/RIIB signaling to further enhance fat reduction while preserving muscle mass.

GDF-8 Targeted Biologics Pipeline and Development Status (Source: Pharmacodia)

GDF-15: A Multifunctional Metabolic Regulator from Cachexia to Weight Management

Distinct from the muscle-regulatory role of GDF-8, GDF-15 is a stress-inducible secreted protein that is expressed at low levels under normal physiological conditions but is markedly upregulated in response to cellular injury, inflammation, and oxidative stress. GDF-15 exerts its effects through binding to GFRAL in the area postrema and nucleus tractus solitarius of the brainstem, where it regulates appetite and systemic energy metabolism. The identification of this signaling axis has positioned GDF-15 as a multifunctional target linking metabolic control, immune responses, and disease intervention. Its therapeutic potential in weight management is increasingly supported by recent clinical advances.

https://doi.org/10.1016/j.tem.2018.05.002

Peripherally derived GDF-15 acts on GFRAL receptors in the area postrema of the brainstem, leading to reduced food intake and decreased body weight

GDF-15 exhibits bidirectional potential in weight regulation. On one hand, exogenous elevation of GDF-15 can suppress appetite and reduce food intake, promoting weight loss. On the other hand, blockade of pathologically elevated GDF-15 may counteract undesired weight loss, such as in cancer cachexia. Clinical evidence supporting the latter comes from a Phase II study of Ponsegromab, published in NEJM (November 2024). In this trial, a GDF-15–targeting monoclonal antibody was evaluated in 187 patients with advanced lung or pancreatic cancer complicated by cachexia. Treatment resulted in significant weight gain and appetite improvement: the highest-dose group gained an average of 1.33 kg over 12 weeks, compared with a 0.65 kg weight loss in the placebo group. Functional activity levels also improved, and the incidence of adverse events was lower than in the placebo arm.

https://doi.org/10.1056/NEJMoa2409515

Primary endpoint in cancer cachexia patients: change in body weight from baseline to 12 weeks in the Ponsegromab and placebo groups

This study not only represents a breakthrough in the treatment of cancer cachexia but also provides reverse evidence for the central role of the GDF-15 pathway in body weight regulation. In the context of obesity, the development of weight-loss therapies aimed at exogenously activating the GDF-15 pathway is actively progressing. As early as 2017, major pharmaceutical companies including Eli Lilly, Johnson & Johnson, and Novo Nordisk demonstrated that high-affinity targeting of the GDF-15 receptor GFRAL plays a central role in mediating reduced food intake and body weight. A mechanistic study published in Nature (May 2023) further revealed that GDF-15 can activate adrenergic receptors in skeletal muscle, increasing energy expenditure and establishing a dual weight-loss mechanism combining appetite suppression with enhanced energy consumption.

https://doi.org/10.1038/s41586-023-06249-4

GDF-15 can lower the risk of obesity, insulin resistance, and NASH independently of food intake

Globally, most GDF-15–targeted weight-loss therapies remain in early clinical development. Pfizer’s Ponsegromab is the most advanced, currently in Phase III, while NGM-120 is in Phase II, and several others, including CIN-109 and NN-9215, are in Phase I or preclinical stages. Monoclonal antibodies represent the dominant modality, alongside recombinant proteins, fusion proteins, and bispecific antibodies. Development efforts focus on optimizing pharmacokinetics and target specificity while minimizing off-target effects. Beyond monotherapy, the combinatorial potential of GDF-15 is gaining attention: several investigational agents (e.g., ZT-007, YH-40863) employ dual GDF-15/GLP-1R targeting, with future strategies likely to explore additional mechanistic combinations to provide multi-targeted approaches addressing diverse clinical needs in obesity management.

GDF-15 Targeted Biologics Pipeline and Development Status (Source: Pharmacodia)

New Targets vs. Traditional Drugs: Toward a “Quality Weight Loss” Era

The GLP-1 market has grown fiercely competitive, with oral semaglutide approval and steep price cuts for drugs like tirzepatide greatly improving access to weight-loss treatments. Yet challenges like muscle loss and post-treatment weight regain persist. Emerging targets GDF-8 and GDF-15 address these gaps, shifting the focus from simple weight reduction to sustainable, high-quality weight management. GDF-8 inhibitors help preserve muscle and maintain metabolism during weight loss, supporting long-term results. GDF-15 modulators regulate stress and metabolism independently of appetite suppression and may improve metabolic complications such as fatty liver and cardiovascular risk, potentially complementing GLP-1 therapy. Combinations like “GLP-1 + GDF-8” or “GLP-1 + GDF-15” could deliver fat loss, muscle protection, and metabolic health in one strategy.

More Target Recommendations

Related Article

>>Advancing Obesity Therapeutics: From Single-Target to Multi-Target Drug Development

>>Activin R: Emerging Target for Weight Loss and Muscle Gain

>> Multi-pass Transmembrane Proteins and Technology Platform

>> ComboX, A Combination of Universal Solutions

References